Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
BURNABY, British Columbia, April 28, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference in Toronto, Canada on Tuesday, May 2, 2017 at 11:00 am ET.
A live audio webcast of the presentation will be available on the investors section of Xenon's website at www.xenon-pharma.com and will be available for replay following the event.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy. For more information, please visit www.xenon-pharma.com.
Investor/Media Contact: Jodi Regts Senior Director, Corporate Affairs Xenon Pharmaceuticals Inc. Phone: 604.484.3353 Email: [email protected]
